ArticleAmerican journal of blood research2012
Vav1 in hematologic neoplasms, a mini review.
Article in American journal of blood research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Editorial: Guanine nucleotide exchange factors as determinants of cell fate and development.Frontiers in cell and developmental biology · 2025Article
- Vav1 Promotes B-Cell Lymphoma Development.Cells · 2022Article
- Vav Proteins in Development of the Brain: A Potential Relationship to the Pathogenesis of Congenital Zika Syndrome?Viruses · 2022Review
- Article
- Elevated level of Vav1 was correlated with advanced biological behavior and poor prognosis in patients with gastric cancer.International journal of clinical and experimental pathology · 2018Article
- Chaperone-mediated autophagy substrate proteins in cancer.Oncotarget · 2017Review
- Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Vav1: A Dr. Jekyll and Mr. Hyde protein--good for the hematopoietic system, bad for cancer.Oncotarget · 2015Review
- Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance.Oncogene · 2015Article
- The adaptor protein Crk in immune response.Immunology and cell biology · 2014Review
- Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.The Journal of clinical investigation · 2013Article
- Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Development of EHop-016: a small molecule inhibitor of Rac.The Enzymes · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The Vav family of proteins are guanine nucleotide exchange factors which have been shown to be deregulated in several types of human cancer. There are three members of the Vav family that have been identified which are members of the Dbl domain superfamily and have specificity towards Rho/Rac GTPases. The Vav family plays an important role in normal hematologic system development and homeostasis, and Vav1 is largely restricted to the hematologic system. While Vav1 was originally identified as a proto-oncogene, several recent studies have shown that Vav family deletion leads to the development of T-cell malignancies in mice. In addition, Vav1 has been shown to play a role in the ATRA-mediated differentiation of promyelocytic leukemia cells. In this concise review, the gene structure and normal function of Vav1, as well as a possible role for Vav1 in the development of hematologic and other malignancies is reviewed.
Indexed as
Identifiers
22432082PMC3301436W1536281442What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.